209 related articles for article (PubMed ID: 34494717)
1. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
3. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
Chapman JR; Thoren KL
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
[TBL] [Abstract][Full Text] [Related]
4. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
Abeykoon JP; Murray DL; Murray I; Jevremovic D; Otteson GE; Dispenzieri A; Arendt BK; Dasari S; Gertz M; Gonsalves WI; Kourelis TV; Muchtar E; Dingli D; Warsame R; Go RS; Lacy MQ; Leung N; Buadi F; Lin Y; Kyle RA; Rajkumar V; Kumar S; Kapoor P
Br J Haematol; 2021 Apr; 193(2):380-385. PubMed ID: 33216966
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay.
Turner KA; Eckelkamp LL; Kalass SJ; Martinez MA; Brewer HR; Hoyne JB; Snyder MR; Murray DL; Willrich MAV
Clin Chem; 2019 Oct; 65(10):1327-1329. PubMed ID: 31387883
[No Abstract] [Full Text] [Related]
6. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
7. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
8. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
10. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
11. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
[TBL] [Abstract][Full Text] [Related]
12. Standardisation of minimal residual disease in multiple myeloma.
Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
15. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
16. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.
Mills JR; Kohlhagen MC; Willrich MAV; Kourelis T; Dispenzieri A; Murray DL
Blood; 2018 Aug; 132(6):670-672. PubMed ID: 29891533
[No Abstract] [Full Text] [Related]
17. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
[TBL] [Abstract][Full Text] [Related]
18. Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.
D'Auria F; La Rocca F; Simeon V; Statuto T; Pietrantuono G; D'Arena G; Villani O; Mansueto G; Traficante A; Musto P
Br J Haematol; 2018 May; 181(4):550-552. PubMed ID: 28439880
[No Abstract] [Full Text] [Related]
19. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
[TBL] [Abstract][Full Text] [Related]
20. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]